Novartis Signs $7.2 Billion mRNA Deal with Abogen Biosciences

Key Facts

1Novartis signed a $7.2 billion deal with Abogen Biosciences to develop mRNA-based immunotherapy treatments.

Novartis signed a $7.2 billion deal with Abogen Biosciences to develop mRNA-based immunotherapy treatments. Investing.com reported that the agreement focuses on advancing biotechnology solutions, marking a significant investment by the Swiss pharmaceutical company in next-generation medical platforms.

The collaboration aims to leverage Abogen's mRNA platform to expand the Novartis pipeline in immunology and oncology. This strategic move reflects a broader industry shift toward RNA-based technologies as the company seeks to strengthen its position in high-growth therapeutic sectors.